MedTrace Logo

Hypermethylation of VTRNA2-1 Promoter in HCC Outcome

NCT04177316 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 92

Last updated 2019-11-26

No results posted yet for this study

Summary

The clinic-pathological data were retrieved from the cancer registry database from the Cancer Center of Chang Gung Memorial Hospital, Linkou branch. Of the 92 HCC patients with partial hepatectomies enrolled. The biological specimen was studied with approval.

Conditions

  • Hepatocellular Carcinoma Resectable

Sponsors & Collaborators

  • Chang Gung Memorial Hospital

    lead OTHER

Principal Investigators

  • Ming-Chin Yu, MD, PhD · Chang Gung Memorial Hospital

Eligibility

Min Age
20 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-01
Primary Completion
2019-11-15
Completion
2019-11-15

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04177316 on ClinicalTrials.gov